Invivyd Inc. Launches SPEAR Study Group to Explore Monoclonal Antibody Therapy for Long COVID and Post-Vaccination Syndrome

Invivyd, Inc. has announced the formation of the SPEAR Study Group, a clinical and translational study group focused on the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome. The group will conduct collaborative, multi-center translational clinical research to explore the biology and clinical disease associated with chronic exposure to the SARS-CoV-2 virus or mRNA vaccine-mediated spike protein. The study aims to evaluate the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody therapy, including Invivyd's next-generation candidates such as VYD2311, in individuals with Long COVID or Post-Vaccination Syndrome. The results of these trials will be presented in the future, as the research is in the planning and execution phase. The study group includes leading investigators such as Dr. Michael Peluso, Dr. Amy Proal, and Dr. David Putrino, who will work alongside Invivyd to design and implement the clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9488006-en) on July 02, 2025, and is solely responsible for the information contained therein.